Given the strong prospects in the business, analysts expect the company to clock healthy growth of 15-20 per cent, going ahead.
Fresh meat and seafood delivery unicorn Licious is intensifying its talent acquisition endeavours as it pursues profitability and readies for an initial public offering (IPO) within the next 24 months. Delightful Gourmet, Licious' parent company, has named 39-year-old Karishma Gupta as its new chief financial officer (CFO). Her appointment aligns with Licious' drive for profitable growth through an omnichannel strategy.
Post the offer, GSK's holding will be 75 per cent from the present 43.2 per cent.
While a merger means HUL taking over GSK Consumer's assets, including its employees, any mention of retention of employees beyond the merger is missing in the deal.
There is no near-term respite for the country's largest fast-moving consumer goods maker, Hindustan Unilever (HUL), which is facing multiple challenges on the growth front. With demand showing no signs of improvement, especially in the rural segment, the October-December quarter (Q3) of 2023-24 (FY24) is likely to be similar to the previous quarter, with volume growth in the low single digits. The stock, which is down 7 per cent over the past year compared to the 11 per cent jump for the S&P BSE Sensex, could underperform the benchmark in the near term as well.
FMCG major HUL on Friday announced the appointment of Rohit Jawa as the managing director & chief executive officer to succeed Sanjiv Mehta who will retire from the company after leading it for a decade. Jawa, presently the Chief of Transformation for Unilever, would take over the leadership role for a term of five consecutive years with effect from June 27, 2023, the company said in a statement. "The appointment of Rohit Jawa as a whole-time director and MD & CEO will be subject to approval of Shareholders and other statutory approvals as may be applicable," it added.
Horlicks widens brand appeal in increasingly competitive market.
The NPPA letter was issued to GSK on Wednesday.
Amway surged by converting a multitude into sales agents.
The sensitivity segment has quadrupled in the past two years, due to the aggressive marketing effort of both GSK and Colgate.
Open offer to increase holding to 75%, fails to enthuse institutional investors.
Dominant market leader has been adding new users every year, but there are stiff challenges ahead.
GlaxoSmithKline is piggybacking the Rs 1,600-crore (Rs 16-billion) brand to step into newer product categories.
As competition heats up, health drink brands like GSK, Mondelez, Nestle get more aggressive with promotions and promises.
The biggest challenge is crude oil's sustained rally - it is nearing $80 a barrel - stoking inflationary pressures and consequent price hikes in the sector.
While Unilever has been aggressive, both organically and inorganically in the country, P&G's approach has been about achieving 'balanced growth' in terms of top line and bottom line.
ITC has provided retailers with leaflets to assure customers of Yippee noodle's quality and safety standards
Other noodle, pasta brands in scanner after Maggi.
Bubbly is the latest in a string of brands that are touching the three-digit mark quickly.
In spite of a severe second wave of the coronavirus pandemic, and a widespread disruption in public life therefore, India's fast-moving consumer goods (FMGC) sector seems to have emerged as one of the most resilient segments of the economy. The early numbers and estimates for the April-June quarter indicate a steady recovery in FMCG players' business, which is now set to exceed the pre-pandemic level. Amid nationwide lockdowns because of the first Covid wave, FMCG revenues had been severely affected in mid-2020.
In separate statements, the two companies said they will combine Novartis' over-the-counter division with GSK's consumer business, creating a new world-leading consumer healthcare business with $10 billion in annual sales.
Other Health Food Drinks brands of GSK -- Boost, Maltova and Viva -- would come to HUL's portfolio by virtue of the merger, making it a leading player in the segment.
FIIs have offloaded shares of Bajaj Corp, Nestle, Jyothy Laboratories and Britannia.
The two companies agreed to form a joint venture by combining Novartis' over-the-counter division with GSK's consumer business to create a business with $10 billion in annual sales. GSK will hold a 63.5 per cent stake in the venture.
GSKAP takes care of all non-nutrition products whereas GSK Consumer Healthcare is a listed entity which deals only in nutritional products.
But return on equity deteriorated for 7 of the 12 firms analysed.
A probe finds several pharma majors in breach of the law; and in turn they blame the government.
ITC on Monday said it is conducting more tests on its products at accredited labs across India.
Iron-rich noodles and vitamin-rich beverages are some products launched by segment majors
Besides foreign flows, corporate earnings and US Federal Reserve chief Janet Yellen's testimony to the nation's legislature are also likely to impact investor sentiment.
Softening rural consumption and the likelihood of weak corporate earnings in the March quarter saw investors dump stocks.
Some investment bankers expect the Indian currency to touch 60-65 by the end of the year
Growth in cities has lagged villages as consumers troubled by persistently high inflation have cut spending in the past two years.
Anglo-Dutch parent's stake in Indian subsidiary rises from 52.5% to 67.3%.
A glance back at some of the important ups and down Indian Inc faced in 2018.
This goes a long way in creating an ethical organisation culture that in turn helps attract talent.
The oralcare major has kept its ears firmly to the ground, pushing products into the hinterland and is holding fort in urban India with innovation for continued volume growth.
On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances